This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| World Health Organization's Solidarity trial | |
|---|---|
| Name | Solidarity |
| Organizer | World Health Organization |
| Start date | 2020 |
| Type | Multinational adaptive randomized trial |
| Participants | >100 countries |
World Health Organization's Solidarity trial was a large-scale, multinational adaptive randomized clinical trial launched in 2020 to evaluate candidate therapeutics for coronavirus disease 2019 (COVID-19). The effort united public health agencies, academic institutions, regulatory bodies, and healthcare systems in an accelerated pragmatic platform designed to rapidly generate evidence on repurposed drugs and novel agents during an unprecedented global emergency. Its scope and design intersected with major international responses to the pandemic and stimulated parallel initiatives in clinical research and policy.
The trial emerged amid an unfolding pandemic declared by World Health Organization leadership and coordinated with responses by United Nations, Pan American Health Organization, European Centre for Disease Prevention and Control, and national agencies such as the Centers for Disease Control and Prevention and Public Health England. Early therapeutic candidates identified in preclinical studies at institutions like National Institutes of Health, University of Oxford, Institut Pasteur, and Wuhan Institute of Virology prompted calls for pragmatic evaluation across diverse settings including Italy, Spain, Brazil, South Africa, India, China, and United States. The platform approach drew upon methodological precedents from trials such as RECOVERY Trial, Adaptive COVID-19 Treatment Trial, and historical platform studies including I-SPY 2 and MOSAIC.
Solidarity adopted an adaptive, open-label, randomized design coordinated by WHO trials units in collaboration with partners including Coalition for Epidemic Preparedness Innovations, Gavi, the Vaccine Alliance, Wellcome Trust, and national research networks. The protocol used centralized randomization and streamlined data collection to facilitate enrollment in varied hospitals affiliated with organizations like Médecins Sans Frontières, Red Cross, and academic centers such as University of Toronto, Imperial College London, and Johns Hopkins University. Statistical monitoring referenced guidance from bodies including the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and ethical oversight by institutional review boards aligned with Declaration of Helsinki principles. The adaptive features allowed removal or addition of arms in response to interim analyses similar to mechanisms used in Platform trials and influenced by experiences from Ebola virus epidemic in West Africa clinical research.
Initial arms included repurposed antivirals and immunomodulators prioritized by agencies such as Food and Drug Administration, European Medicines Agency, and national formulary committees. Candidates encompassed remdesivir, lopinavir/ritonavir, hydroxychloroquine, and interferon beta-1a—agents with prior clinical use in contexts represented by institutions like Gilead Sciences, AbbVie, and Sanofi. Later modifications reflected emerging data from trials such as RECOVERY Trial and regulatory actions by FDA Emergency Use Authorization processes, leading to discontinuation or emphasis shifts comparable to changes in trials like ACTT-1.
Primary endpoints focused on in-hospital mortality and secondary endpoints included initiation of mechanical ventilation, duration of hospitalization, and time to clinical improvement; analyses reported across collaborating centers including Karolinska Institutet, University of São Paulo, National University of Singapore, and Mayo Clinic. Interim and final reports indicated no significant reduction in overall mortality for several evaluated agents compared with standard of care, while some arms were stopped for futility or safety signals after data monitoring committee reviews consistent with precedents from Clinical Data Monitoring Committees in trials such as SOLIDARITY-like platform studies. The findings influenced regulatory decisions by World Health Organization, European Medicines Agency, and national health authorities, and informed treatment recommendations in guidelines from National Institutes of Health and professional societies like Infectious Diseases Society of America.
The trial faced scrutiny over its open-label design and pragmatic data collection relative to explanatory randomized controlled trials conducted by centers such as NIH and University of Oxford. Critics from academic groups like Statistical Society-affiliated researchers and commentators in outlets referencing Lancet and New England Journal of Medicine debated trade-offs between speed and granular data, echoing controversies seen in emergency research during the H1N1 influenza pandemic and Ebola responses. Political attention from leaders in United States, Brazil, and United Kingdom and public controversies surrounding agents such as hydroxychloroquine heightened media scrutiny, while regulatory actions including revocations of emergency authorizations prompted debate involving institutions like FDA and European Medicines Agency.
Solidarity catalyzed coordination among global research networks, accelerated adoption of platform trial methodologies, and influenced subsequent public health research infrastructures involving entities such as Coalition for Epidemic Preparedness Innovations, Wellcome Trust, and regional research consortia in Africa, Latin America, and Southeast Asia. The trial’s pragmatic model informed later adaptive studies addressing antimicrobial resistance and pandemic preparedness initiatives championed by World Health Organization policy frameworks and multilateral agencies including G20 and United Nations General Assembly discussions. Its datasets and methodological lessons continue to underpin discourse in academic centers like Harvard Medical School, University of Oxford, and London School of Hygiene & Tropical Medicine on rapid evidence generation for emerging infectious diseases.
Category:Clinical trials